Mitsubishi UFJ Trust & Banking Corp Lowers Holdings in Moderna, Inc. (NASDAQ:MRNA)

Mitsubishi UFJ Trust & Banking Corp reduced its stake in Moderna, Inc. (NASDAQ:MRNA - Free Report) by 4.0% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 620,171 shares of the company's stock after selling 26,060 shares during the quarter. Mitsubishi UFJ Trust & Banking Corp owned approximately 0.16% of Moderna worth $25,787,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently bought and sold shares of the company. Wilmington Savings Fund Society FSB increased its stake in shares of Moderna by 295.0% in the fourth quarter. Wilmington Savings Fund Society FSB now owns 786 shares of the company's stock worth $33,000 after purchasing an additional 587 shares in the last quarter. Compass Planning Associates Inc purchased a new stake in Moderna in the 4th quarter worth $37,000. Venturi Wealth Management LLC raised its holdings in Moderna by 286.2% during the fourth quarter. Venturi Wealth Management LLC now owns 896 shares of the company's stock valued at $37,000 after acquiring an additional 664 shares during the period. Crowley Wealth Management Inc. purchased a new position in shares of Moderna in the fourth quarter valued at about $41,000. Finally, MassMutual Private Wealth & Trust FSB lifted its position in shares of Moderna by 58.2% in the fourth quarter. MassMutual Private Wealth & Trust FSB now owns 1,057 shares of the company's stock valued at $44,000 after acquiring an additional 389 shares in the last quarter. 75.33% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several analysts recently issued reports on MRNA shares. Argus downgraded Moderna from a "buy" rating to a "hold" rating in a research note on Wednesday, December 18th. Royal Bank of Canada reiterated a "sector perform" rating and set a $40.00 price objective on shares of Moderna in a research report on Tuesday, February 18th. Evercore ISI set a $50.00 target price on shares of Moderna in a research report on Friday, February 14th. Berenberg Bank raised their price objective on Moderna from $33.00 to $42.00 and gave the company a "hold" rating in a research report on Thursday, January 16th. Finally, Leerink Partners dropped their price objective on shares of Moderna from $31.00 to $27.00 and set an "underweight" rating for the company in a research note on Thursday, January 16th. Four analysts have rated the stock with a sell rating, sixteen have assigned a hold rating, three have assigned a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of "Hold" and an average price target of $59.00.

Remove Ads

Moderna Trading Down 7.8 %

Shares of MRNA stock traded down $2.44 during trading hours on Monday, reaching $28.68. 15,094,930 shares of the company's stock were exchanged, compared to its average volume of 6,852,222. The stock has a market cap of $11.09 billion, a PE ratio of -3.09 and a beta of 1.86. The stock's fifty day moving average price is $34.72 and its two-hundred day moving average price is $44.13. Moderna, Inc. has a 1 year low of $26.22 and a 1 year high of $170.47.

Moderna Company Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.